ABSTRACT. The nonprotein amino acid L-allo-isoleucine is formed endogenously in maple syrup urine disease patients from (R)-3-methyl-2-0x0-pentanoic acid. During strict metabolic balance, the plasma L-allo-isoleucine/~-isoleucine ratio correlates inversely with the residual activity of the branched-chain 2-oxoacid dehydrogenase in fi- 
determined by gas-chromatrography as the trimethylsilylated quinoxalinole derivates (7) . The BCOA decarboxylation activities in the patients' skin fibroblasts were assayed in microtest plates using L-[l-'4C]le~cine as a substrate (8) . Control cell lines (n = 25) were from subjects without any metabolic defect and showed a mean activity of 6.18 k 2.30 nmol 14C02/mg cell protein13 h (% + SD). Decarboxylation activity of a cell strain at different culture passages was measured with a variation coefficient of about 20%. In most cases of classic MSUD, decarboxylation activity was clearly below 1 % of normal (see Ref. 9) .
In the present communication, "strict metabolic balance" is defined as constant plasma BCAA levels at a constant BCAA intake during 10 days or more.
In MSUD the oxidative decarboxylation of the branched-chain PATIENTS 2-oxoacids is impaired, and the branched-chain amino acids as well as the corresponding branched-chain 2-oxoacids accumulate Six patients with classic and six with variant MSUD were in tissues and body fluids. S-OMV, the transamination product studied. Their classification into variant and classic forms was of L-isoleucine is a chiral compound. At elevated plasma levels, according to clinical and clinical-chemica1,findings. it has been shown to undergo racemization with formation of RClassic forms. The patients Ca (1980), Oz (1982), Mi (1983), OMV in vivo (I), apparently via nonenzymic enolization (2). and 0 g (1985) presented by the end of the 1st wk of life with The metabolic fate of R-OMV is 1) transamination to L-allo-pronounced neurologic abnormalities. Diagnosis of MSUD was isoleucine, a non-protein amino acid, regularly found in the made between the 1 lth and 17th day of life. At that time, each patients' blood, and 2), depending on the residual activity of the patient was comatose and had the maple syrup-like odor and a mutant enzyme, oxidative decarboxylation by which it is chan-plasma leucine concentration ranging from 2.9-3.7 mmollliter. nelled into the so-called R-pathway of isoleucine catabolism (3) SO (198 1) and En (1975) had a positive family history of classical (Fig. 1) .
MSUD, and diagnosis, therefore, was made soon after birth. All Sluggish plasma kinetics of allo-isoleucine have been described patients showed a normal neurologic and somatic development already by Snyderman and colleagues (4) . We observed repeat-on a BCAA-restricted diet. The tolerance for leucine ranged from edly that present allo-isoleucine levels reflect past isoleucine 45-55 mglkg body weight at the age of 1 yr and from 30 to 35 levels and, therefore, aimed at further characterising allo-isoleu-mg/kg at the age of 3 yr. Each patient underwent numerous cine as an inert marker of isoleucine metabolism (5) in patients episodes of metabolic derangements triggered by intercurrent with classical MSUD and different MSUD variants. In these illnesses. studies, it turned out that the ratio of allo-isoleucine to isoleucine Variant forms. Gu (1 974) at the age of 1 yr was about 50 mg/kg body weight and 40 mg/ kg at the age of 3 yr. They showed only a few episodes of metabolic derangements during intercurrent illnesses.
Ck (1986) was diagnosed as having MSUD at 21 months of age when plasma leucine concentration was 0.8 mmol/liter. During the 1st yr of life, he showed an adverse reaction to protein-rich food. On a protein-restricted diet with 1.4 g/kg body weight, the plasma leucine level persisted at about 0.4 mmol/ liter during the first 5 months of treatment.
Te (1977) presented with neurologic signs and maple syrup odor at 3 wk of age; she developed normally on a proteinrestricted diet. Febrile illnesses were well tolerated. At a protein intake of 1.3 g/kg body weightlday, plasma BCAA levels were only slightly elevated ( 2~ normal) during childhood.
In Ku (1979) and Na (1978), MSUD was detected by neonatal screening. Both patients developed normally on a slightly protein-restricted diet. They never had episodes of metabolic derangements, and plasma leucine levels never exceeded 0.35 mmol/liter. On 2 g protein/kg body weight, plasma BCAA levels were only slightly ( 2~ normal) elevated.
All classical and severe variant patients were maintained on diets sufficiently depleted in the BCAA to keep their plasma concentrations less than 0.5 mmol/liter. In all patients, except for Og and Ck, the plasma allo-isoleucine/isoleucine ratios were determined at different occasions during the first 5 yr of life at strict metabolic balance.
RESULTS
Slow plasma kinetics of L-allo-isoleucine can be observed in MSUD patients on extended monitoring as well as after acute Lisoleucine loads. Figure 2 shows the plasma concentrations of the four branched-chain amino acids in a classical MSUD patient on dietotherapy. Whereas L-isoleucine-like L-leucine and Lvaline-oscillated frequently and with high amplitudes, alterations of L-allo-isoleucine followed those of isoleucine with a shift of phase and with a diminished amplitude. This time course is representative of many other similar observations.
An oral L-isoleucine load (1.5 mmol/kg body weight) given to a variant MSUD patient produced a rapid rise of the plasma isoleucine concentration (Fig. 3) . The peak plasma concentration of OMV followed with a delay of 30 min. Allo-isoleucine appeared in plasma only 3 h later and plateaued at 0.03 mmol/ liter 4 h after the load. Isoleucine and OMV were eliminated from plasma with a half life of about 3.5 h. Allo-isoleucine remained stable for at least 20 h and was later cleared from the plasma with a half-life of about 12 h.
Closer scrutinity of our data revealed that, irrespective of possible erratic fluctuations of plasma levels (see Fig. 2 ), each patient approached a characteristic ratio of allo-isoleucine to isoleucine levels at periods of strict metabolic balance. The ratio, in the individual patients, did not change with a consistent trend during the study periods of 2 to 5 yr. These ratios of plasma concentrations are given in Table 1 for the different subjects with MSUD. In addition, their residual BCOA dehydrogenase activities are shown as measured in cultured skin fibroblasts.
In classic MSUD patients, the ratio ranged from 0.6-0.75. In the group comprising the different MSUD variants (Gu, Mo, Ck, Te, Ku, Na), the ratios were lower than in classic MSUD and were inversely related to the residual BCOA dehydrogenase activity. In very mild MSUD variants, (with 15-20% residual enzyme activity), the ratio was 0.1. No relationship was found between this ratio and the plasma concentration of the other BCAA for the patients listed in Table 1 .
Under strict metabolic balance, allo-isoleucine plasma concentrations were always lower than plasma isoleucine concentrations. However, when isoleucine intake was acutely diminished or when protein synthesis abruptly increased, plasma isoleucine levels fell below those of allo-isoleucine. This happened frequently in classic MSUD (see Fig. 2 ). In very mild variants we did not find any condition in which plasma allo-isoleucine concentration exceeded that of isoleucine.
DISCUSSION
The nonprotein amino acid L-allo-isoleucine is an endogenous, regular, and specific constituent of plasma in MSUD patients (10) . From its L-configuration (1 1) it follows that it is formed from R-OMV and that the equilibrium of plasma isoleucine and allo-isoleucine in metabolically stable MSUD patients occurs by racemization of the chiral OMV through keto-en01 tautomerism. This reaction proceeds nonenzymatically (2, 12) in an as yet unknown compartment and is easily observed, e.g. at very high concentrations of the isoleucine-derived S-OMV (1 3). Weinberg and Walser (13) described a polarimetric assay of both OMV dinitrophenylhydrazone enantiomers. The original procedure requires large sample volumes and has not yet been adapted to studies in humans. A potentially more sensitive separation of the diastereomeric quinoxalinol propionic acid derivatives of S-and R-OMV could not be achieved on a great number of gaschromatographic columns, including Chirasil-Val (Langenbeck U 1986, unpublished data). Until now, any interpretation of in vivo metabolism of allo-isoleucine in patients could be based only indirectly on plasma levels of allo-isoleucine alone, and theoretically also on measurements of R-pathway metabolites, which are diminished in concentration in MSUD urine compared to normal controls (3).
The slow plasma kinetics of allo-isoleucine in MSUD, which were initially reported by Snyderman (4) and which are highlighted again in our studies, just accentuate the normal state: Whereas the initial plasma half-life of L-isoleucine after an oral load in normal subjects is 45-70 min (14, 15) , L-allo-isoleucine has a plasma half-life of a few hours (4). In classic MSUD, the respective values are about 2 days for L-isoleucine and between 5.5-7.5 days for L-allo-isoleucine (4). Interestingly, allo-isoleucine does not support rat growth (1 6), whereas its keto-analogue, R-OMV, does (16, 17) .
These observations suggest that, in reference subjects, transamination of L-allo-isoleucine to R-OMV is slow and that any R-OMV formed is channeled preferentially into the R-pathway. Only high intracellular concentrations of R-OMV would saturate the R-pathway and allow formation of isoleucine via racemization to S-OMV. Recent biochemical studies in normal human fibroblasts (18) have confirmed the first prediction, demonstrating that transamination of allo-isoleucine is only 4 1 % of the rate of isoleucine.
In classic MSUD, the R-pathway is closed to R-OMV catabolism, and allo-isoleucine can be cleared by formation of isoleucine and by (inefficient) renal excretion. Both OMV enantiomers appear to be present in MSUD patients, because the percentage atom excess of I5N of isoleucine and allo-isoleucine could not be A ile allo -ile 
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' * BCOA dehydrogenase activity was assessed in intact cultured fibroblasts with [1-14C] leucine (8) in four sets of assays. The plasma isoleucine distinguished 60 to 240 min after a "N-leucine load (19) , whereas de novo formation of allo-isoleucine from isoleucine is much slower (20) (Fig. 3) . We anticipate from these data that racemization of OMV is also slow in MSUD, and that under high intracellular concentrations of the BCOA retransamination of allo-isoleucine to R-OMV is even slower than in controls. Testing such a "trap model" of allo-isoleucine metabolism in MSUD will require in vitro studies on the mutual transamination of alloisoleucine with the BCOA. The reportedly very low concentrations of 2-hydroxy-3-methylpentanoic acid in MSUD (21) make relevant contributions of this compound to allo-isoleucine kinetics unlikely.
The supposed allo-isoleucine trap would become more leaky with increasing residual BCOA dehydrogenase activities in MSUD variants, because the transamination equilibrium of alloisoleucine would be shifted to R-OMV by partial R-OMV catabolism. Our data in Table 1 indicate that by this chain of events plasma half-life of allo-isoleucine will depend in MSUD variants on the residual activity of the BCOA dehydrogenase complex. By L-allo-isoleucine loading tests in selected MSUD patients, we have preliminarily proved this prediction (22) . 
